Partners and Distributors
Pharmaxis selectively partners with pharmaceutical and biotechnology companies to further our clinical endeavours and business aims.
Our partners are:
|In May 2015 Boehringer Ingelheim acquired the Pharmaxis phase 1 investigational drug PXS4728A to develop it for the treatment of the liver-related condition NASH. Read more.|
|In December 2014 Pharmaxis and Chiesi Farmaceutici SpA entered into an exclusive distribution and supply agreement for the commercialisation of Bronchitol® (mannitol) in the United States. Chiesi is responsible for funding up to US$22 million of the cost of the phase 3 clinical trial of Bronchitol. Read more.|
|In August 2015 Pharmaxis and UK biotechnology company Synairgen plc entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF). Read more.|
Our global network of distributors provide logistical support services for our approved products in world markets. For more information on our distributors please see: